Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program Solange.

Slides:

Advertisements

Similar presentations

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Advertisements

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

SC17.02 Lung Cancer in China: Challenges and Perspectives

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H

MET-Mutated NSCLC with Major Response to Crizotinib

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer Suzanne Jenkins, DPhil, James C-H.

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib Suzanne Jenkins, DPhil, James Chih-Hsin.

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Electronic Updates for JTO Readers

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

The Moth-Eaten Lung Journal of Thoracic Oncology

Numb Chin Syndrome: An Ominous Sign of Lung Cancer

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib Chien-Hung Gow, MD, PhD, Wei-Yu Liao, MD, PhD, Yi-Nan Liu,

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Journal of Thoracic Oncology

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort Oliver Gautschi, MD, Julie Milia, PhD, Bastien Cabarrou,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Solitary Choriocarcinoma in the Lung

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

S768I Mutation in EGFR in Patients with Lung Cancer

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

European Lung Cancer Conference (ELCC) 2016 Organisation

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Metastatic Lung Cancer to the Pancreas

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Successful AZD9291 Therapy Based on Circulating T790M

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Robert Comis, MD, The Passing of a “Lung Man”

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program Solange Peters, MD, PhD, Alessandra Curioni-Fontecedro, MD, Hovav Nechushtan, MD, PhD, Jin-Yuan Shih, MD, PhD, Wei-Yu Liao, MD, PhD, Oliver Gautschi, MD, Vito Spataro, MD, Mojca Unk, MD, James Chih-Hsin Yang, MD, PhD, Robert M. Lorence, MD, PhD, Philippe Carrière, MD, Agnieszka Cseh, MD, Gee-Chen Chang, MD Journal of Thoracic Oncology Volume 13, Issue 12, Pages 1897-1905 (December 2018) DOI: 10.1016/j.jtho.2018.07.093 Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 ERBB2 mutation types identified in patients participating in the NPU program. Journal of Thoracic Oncology 2018 13, 1897-1905DOI: (10.1016/j.jtho.2018.07.093) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Computed tomography scans at baseline (A) and after 6 weeks of afatinib treatment (B) in a Taiwanese patient with a p.A775_G776insYVMA insertion in exon 20 who achieved a PR. Journal of Thoracic Oncology 2018 13, 1897-1905DOI: (10.1016/j.jtho.2018.07.093) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Positron-emission tomography scans taken (A) before initiation of afatinib and (B) after ∼3 months of treatment in a European patient with a p.A775_G776insYVMA insertion in exon 20 who achieved a PR. Journal of Thoracic Oncology 2018 13, 1897-1905DOI: (10.1016/j.jtho.2018.07.093) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions